Content by Keyword: Drugs, Medical Devices, and Pharmacy Services

  • Home
  • Drugs, Medical Devices, and Ph...
  • print
  • email
  • twitter
  • compact
PDF report
Accelerating Adoption of Assistive Technology to

Accelerating Adoption of Assistive Technology to Reduce Physical Strain among Family Caregivers of the Chronically Disabled Elderly Living at Home

This report examines and assesses the often overlooked potential of assistive technology (AT) to benefit unpaid family caregivers who assist chronically disabled elders living at home. Although research has identified benefits, only a handful of publicly-funded family caregiver support programs give much attention to enabling caregivers’ access
  • AccAdoAT.pdf
    export-csvPDF
PDF report
Expanding the Use of Generic Drugs

Expanding the Use of Generic Drugs

Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
From: Expanding the Use of Generic Drugs
PDF report
Medicaid Contracts with Medicare Special Needs

Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries

This paper is the third in a series on SNPs and their relationship to Medicaid. In the second paper of the series, we identified all states which had some kind of contractual relationship with SNPs prior to MIPPA, and classified those relationships into broad categories. The purpose of this third paper is to examine in greater detail a select grou
From: Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries
  • SNPdual.pdf
    export-csvPDF
PDF report
Economic Analysis of Availability of Follow-on

Economic Analysis of Availability of Follow-on Protein Products

Unlike most conventional drugs, biological products are usually large, complex molecules that are produced by living organisms. These commercially engineered biologics currently account for billions of dollars in health care spending. Starting early last century, Congress has regulated most biologics separately from small molecules under the Bio
  • report.pdf
    export-csvPDF
PDF report
Federal Authority for Medicare Special Needs

Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs

This Brief reviews the history and current status of federal special needs plans (SNPs) authority, with particular attention to provisions of interest to state Medicaid programs that have or are considering entering into contracts with SNPs to integrate or coordinate Medicaid long-term care services with Medicare primary, acute and prescription dr
From: Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs
  • leghist.pdf
    export-csvPDF
PDF report
Evaluation of New Measures of Assistive

Evaluation of New Measures of Assistive Technology and the Home Environment from the 2005 Pilot Study of Technology and Aging

The purpose of this report is to highlight the analytic properties of the assistive technology and environment measures in the final recommended module. The authors address three distinct but complimentary questions: (1) How do questions that combine several environmental features or devices (global measures) compare with more detailed items? (2)
From: Evaluation of New Measures of Assistive Technology and the Home Environment from the 2005 Pilot Study of Technology and Aging
  • newmeas.pdf
    export-csvPDF
PDF report
Cost Effectiveness Considerations in the Approval

Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies

The Office of the Assistant Secretary for Planning and Evaluation (ASPE) commissioned The Lewin Group (Lewin) to determine how and to what extent cost-effectiveness (CE) considerations are incorporated in the approval and adoption of new health technologies and the implications of not incorporating such considerations. This report examines the use
  • report.pdf
    export-csvPDF
PDF report
Understanding Variations in International Drug

Understanding Variations in International Drug Prices

Rapidly rising prescription drug prices have caused many consumers, third-party payers, and policymakers to look for ways to lower their drug costs. One strategy that many have seen as a potential solution is to import drug products from countries where drug prices are lower than those in the United States — commonly called reimportation.
  • report.pdf
    export-csvPDF
PDF report
Drug Use and Spending for Medicare Beneficiaries

Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays

This Policy Brief helps fill an important gap in our understanding of medication patterns in long-term care facilities (LTCFs) by comparing use and spending for prescription and over-the-counter drugs during skilled nursing facility (SNF) stays and related non-qualifying long-term care facility episodes. Its first aim is to characterize Medicare-
From: Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays
  • druguse.pdf
    export-csvPDF
PDF report
A National Comparison of Prescription Drug

A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings

This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available. For this analysis, the authors present summary findings of: (1) characteristics of Medicare beneficiaries residing in long-term care facilities and the community; (2)
From: A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
  • pdnatcom.pdf
    export-csvPDF
PDF report
National Estimates of Prescription Drug

National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities

This Policy Brief offers an updated look at prescription drug utilization by Medicare beneficiaries residing in long-term care facilities and reports, for the first time, national estimates of prescription drug spending by this population. [23 PDF pages]
From: National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities
  • pdnatest.pdf
    export-csvPDF
PDF report
Prescription Drug Spending by Medicare

Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001

This study had three specific aims: (1) To prepare nationally-representative estimates of drug spending in long-term care (LTC) facilities; (2) To compare drug use and spending for beneficiaries in LTC facilities versus beneficiaries in the community; and (3) To examine medication use and spending by short-stay skilled nursing home facility reside
From: Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
  • pdspend.pdf
    export-csvPDF
PDF report
Analysis of Supply, Distribution, Demand, and

Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)

IGIV is a plasma product that is used to treat patients with immune system disorders. A significant percentage of IGIV use is for off-label indications. Current conditions in the IGIV industry and market are complex and rapidly evolving. The growing demand for IGIV, supply capacity issues, changes in reimbursement, and the relocation of sites of s
  • report.pdf
    export-csvPDF
PDF report
An Overview of the US Health System Chart Book

An Overview of the US Health System Chart Book

This chart book provides data on various aspects of the US health system including public and private health care coverage, provider data, and international comparisons of the US to OECD countries. [128 PDF pages]
  • report.pdf
    export-csvPDF
PDF report
Compendium of Home Modification and Assistive

Compendium of Home Modification and Assistive Technology Policy and Practice Across States: Final Report

The purpose of this report is to establish a baseline knowledge of the scope of assistive technology (AT) and home modifications (HM) services that states make available to Medicaid-eligible adults. This study provides federal and state policymakers with basic information to inform planning and policy development. It also provides other stakeholde
From: Compendium of Home Modification and Assistive Technology Policy and Practice Across States: Final Report
  • HM-ATI.pdf
    export-csvPDF
PDF report
Continuation of Drug Risk Adjustment

Continuation of Drug Risk Adjustment

This project reports on analysis using linked Medicaid and FEHBP data examining refinements to the risk adjustment factors for drug plans for low income and institutionalized populations; geographic variation in drug spending by health plan area; and prior use models of drug plan risk-adjustment. [77 PDF pages]
  • report.pdf
    export-csvPDF
PDF report
Development of an Assistive Technology and

Development of an Assistive Technology and Environmental Assessment Instrument for National Surveys: Final Report - Part I

The purpose of this project was to develop, pilot, and disseminate a set of instruments for national surveys to measure the use of assistive technology and the environments in which they are used. The project focused on older adults living in the community. The instruments have been designed as a series of modules that can be adopted in whole or p
From: Development of an Assistive Technology and Environmental Assessment Instrument for National Surveys: Final Report
  • ATEAdevI.pdf
    export-csvPDF
  • ATEAdevI-A.pdf
    export-csvPDF
  • ATEAdevI-B.pdf
    export-csvPDF
PDF report
Impact of Policies to Limit Drug Plan's

Impact of Policies to Limit Drug Plan's Financial Risk

This paper examines the combined effects of drug plan risk the first year of Medicare part D implementation of the combination of reinsurance, risk-adjustment and risk-corridors
  • impact.pdf
    export-csvPDF
PDF report
Geographic Variation in Prescription Drug Prices

Geographic Variation in Prescription Drug Prices and Spending

This paper examines by state variation in drug prices and drug spending. Variation in prices are found to be minimal but variation in spending (and utilization) are more substantial. Further work will explore the underlying reasons for the spending variation and whether patterns persist when analyzed for areas other than states.
  • geographic.pdf
    export-csvPDF
PDF report
Developing A Risk Adjustment Methodology for

Developing A Risk Adjustment Methodology for Medicare Drug Plans

This paper describes the work NORC did to supplement the Federal Employee Health Benefits data (FEHBP) used to develop drug risk adjustment factors for over 65 individuals with a full drug supplement to Medicare. This data needed to be supplemented because the FEHBP data did not adequately represent, low-income, disabled, or non east Coast popula
  • highlighter.pdf
    export-csvPDF

Pages

Form Approved OMB# 0990-0379 Exp. Date 9/30/2020